Sector: Healthcare
findl.com provides a comprehensive suite of standardized financial statement data and an assortment of calculated metrics sourced directly from SEC filings, and meticulously cleansed and verified, ensuring reliability. To get the complete financial statement history in quarterly and annual resolution for REGN, sign up here.
Income Statement
Revenue
$13.1bn
Gross Profit
$11.3bn
Earning before Tax
$4.2bn
Net Income
$4.0bn
Net Income Common Shareholders
$4.0bn
EPS
37.05
Balance Sheet
Cash
$2.7bn
Debt
$2.7bn
Assets
$33.1bn
Liabilities
$7.1bn
Equity
$26.0bn
Enterprise Value
$96.2bn
Cash Flow Statement
Net Cash from Operations
$4.6bn
Net Cash from Investing
$-3.2bn
Net Cash from Financing
$-1.8bn
Net Cash Flow
$-0.4bn
Free Cash Flow
$3.9bn
Free Cash Flow per Share
$36.32
Metrics
Price to Equity
24.20
Price to Equity (Damodaran)
23.71
Price to Book
3.68
Net Margin
0.30
Return on Equity
0.16
Return on Sales
0.33
Get immediate access to 5-years of reference grade data for REGN for free.
Sign upRegeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company''s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Company Info
Industry
Biotechnology
Employees
13,450
Address
777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
United States
Phone
914 847 7000
Website
Last Updated
2024-02-15
Available Data
Standardized Financial Statements
EOD Price History
Corporate Actions
Institutional Holdings
Insider Transactions
Copyright © findl 2024. All rights reserved.